HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Otto, M. Articles by Prange, H. Search for Related Content PubMed PubMed Citation Articles by Otto, M. Articles by Prange, H. Related Collections Prion All Neuropsychology/Behavior All Clinical trials Clinical trials Randomized controlled (CONSORT agreement)

Efficacy of flupirtine on cognitive function in patients with CJD

A double-blind study

From the Departments of Neurology (Drs. Otto, Cepek, Ratzka, Doehlinger, Poser, and Prange) and Psychiatry (Dr. Irle), University of Goettingen, LKH Wehnen (Dr. Boekhoff), Bad Zwischenahn, Department of Psychiatry (Dr. Wiltfang), University Erlangen/Nuremberg, ASTA Medica AG, since 1/11/01 Baxter Oncology GmbH & Co. KG (Dr. Pergande) and VIATRIS GmbH & Co. KG, Frankfurt/Main, since 1/3/03 Omega Mediation, Offenbach (B. Ellers-Lenz), and Institute of Neuropathology (Dr. Kretzschmar), University Munich, Germany; and Veterinary Laboratories Agency (Dr. Windl), Weybridge, UK.

Address correspondence and reprint requests to Dr. M. Otto, Department of Neurology, Georg-August University Goettingen, Robert-Koch Str. 40, 37070 Goettingen, Germany; e-mail: motto{at}gwdg.de

Background: In cell culture experiments, flupirtine maleate (FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments and ß-amyloid peptides. As FLU is a clinically safe drug, the authors started a double-blind placebo-controlled study in patients with Creutzfeldt–Jakob disease (CJD).

Methods: Twenty-eight patients with CJD were randomized to an oral treatment with either FLU (n = 13) or matching placebo (PLA; n = 15). For inclusion and continuing the study, the patients had to achieve at least 50% in two of the subscales of the dementia tests employed. A battery of standardized questionnaires was employed to monitor the progression of the disease. The main outcome variable was the cognitive part of the Alzheimer’s Disease Assessment Scale (ADAS-Cog); the difference between baseline and the best score under treatment was defined as the primary efficacy variable for hypothesis testing.

Results: CJD types were homogeneously distributed among the treatment groups. Patients treated with FLU showed significantly less deterioration in the dementia tests than patients treated with PLA. The mean change in ADAS-Cog (baseline to best) was +8.4 (±15.3) in the FLU group and +20.6 (±15.1) in the PLA group (p = 0.02, one-sided t-test).

Conclusions: FLU has beneficial effects on cognitive function in patients with CJD. These positive results also may suggest a treatment potential of FLU in other neurodegenerative disorders. However, further studies are necessary.

Received April 25, 2003. Accepted in final form October 28, 2003.

See also page 679

This article has been cited by other articles:

				L. A. Stewart, L. H.M. Rydzewska, G. F. Keogh, and R. S.G. Knight Systematic review of therapeutic interventions in human prion disease Neurology, April 8, 2008; 70(15): 1272 - 1281. [Abstract] [Full Text] [PDF]

				S. Cronier, V. Beringue, A. Bellon, J.-M. Peyrin, and H. Laude Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal Cultures J. Virol., December 15, 2007; 81(24): 13794 - 13800. [Abstract] [Full Text] [PDF]

				Y. Kawasaki, K. Kawagoe, C.-j. Chen, K. Teruya, Y. Sakasegawa, and K. Doh-ura Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent Manner J. Virol., December 1, 2007; 81(23): 12889 - 12898. [Abstract] [Full Text] [PDF]

				M. V. Soldovieri, M. R. Cilio, F. Miceli, G. Bellini, E. Miraglia del Giudice, P. Castaldo, C. C. Hernandez, M. S. Shapiro, A. Pascotto, L. Annunziato, et al. Atypical Gating Of M-Type Potassium Channels Conferred by Mutations in Uncharged Residues in the S4 Region of KCNQ2 Causing Benign Familial Neonatal Convulsions J. Neurosci., May 2, 2007; 27(18): 4919 - 4928. [Abstract] [Full Text] [PDF]

				C. Korth and P. J. Peters Emerging pharmacotherapies for creutzfeldt-jakob disease. Arch Neurol, April 1, 2006; 63(4): 497 - 501. [Abstract] [Full Text] [PDF]

				J Collinge Molecular neurology of prion disease J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 906 - 919. [Abstract] [Full Text] [PDF]

				C. Feraudet, N. Morel, S. Simon, H. Volland, Y. Frobert, C. Creminon, D. Vilette, S. Lehmann, and J. Grassi Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells J. Biol. Chem., March 25, 2005; 280(12): 11247 - 11258. [Abstract] [Full Text] [PDF]